Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06661889 · ClinicalTrials.gov registry record
OM2 Low Saturation Verification
A clinical trial, sponsored by Medtronic - MITG.
- Completed
- Registry status
- 28
- Enrollment target
NCT06661889: Completed study, sponsored by Medtronic - MITG.
NCT06661889 is a clinical trial that has completed, run by Medtronic - MITG. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06661889 has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
The verification of an investigational pulse oximetry board to verify pulse rate and saturation accuracy over a specified saturation range in diverse populations.
Primary Outcome
Verification of Saturation Accuracy Saturation accuracy in a diverse subject population over a specified saturation range. The acceptance criteria for SpO2 during low saturation conditions across the saturation range of 60-80%: SpO2 Max-A ±3% (ARMS) Max-N ±3% (ARMS) OxySoft-N ±3% (ARMS) Max-Fast ±3%(ARMS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2025-05-27 |
What the finished NCT06661889 record still lists
NCT06661889 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT06661889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06661889 about?
NCT06661889 is a clinical study titled "OM2 Low Saturation Verification". The verification of an investigational pulse oximetry board to verify pulse rate and saturation accuracy over a specified saturation range in diverse populations.
What is the current status of trial NCT06661889?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2024-11-18. Estimated completion is 2025-05-27.
Who is sponsoring clinical trial NCT06661889?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI